HomeAI · summaries
Storia in 2 fonti
Male contraception startup closes $92.5M Series B; Novartis bets on actinium in Phase 3
Contraline closes $92.5M Series B to fund male contraception; Novartis begins Phase 3 actinium therapies; Tavo gets $17M Series A.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
fiercepharma.com
Contraline and its male birth control candidate rally $92.5M amid push into 'massive white space' of men's health
Amid shifts in attitudes around family planning and contraception—and as the advent telehealth outfits like Hims & Hers and Ro define a new era of consumer-driven healthcare—the…
- ·
endpoints.news
Male contraception startup closes $92.5M Series B; Novartis bets on actinium in Phase 3
Contraline closes $92.5M Series B to fund male contraception; Novartis begins Phase 3 actinium therapies; Tavo gets $17M Series A.